目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product Type
1.2.2. Cancer Type
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product type outlook
2.2.2. Cancer type outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Precision Oncology Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Prevalence of Cancer
3.2.1.2. Advancements in Genomics and Molecular Diagnostics:
3.2.1.3. Supportive Government and Private Sector Initiatives
3.2.2. Market restraint analysis
3.2.2.1. High Costs of Precision Oncology Therapies
3.2.2.2. Limited Access to Advanced Diagnostic Technologies:
3.3. Precision Oncology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape

Chapter 4. Precision Oncology Market: Product Type Estimates & Trend Analysis
4.1. Product Type Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Precision Oncology Market by Product Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Diagnostics
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Therapeutics
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Precision Oncology Market: Cancer Type Estimates & Trend Analysis
5.1. Cancer Type Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Precision Oncology Market by Cancer Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Breast Cancer
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Colorectal Cancer
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Cervical Cancer
5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.4. Prostate Cancer
5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.5. Lung Cancer
5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.6. Others
5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Precision Oncology Market: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Precision Oncology Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals and Diagnostic
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Pharmaceutical and Biotechnology
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Healthcare Data Companies
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Precision Oncology Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Target disease prevalence
7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Target disease prevalence
7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. Target disease prevalence
7.5.3.5. Mexico market estimates and forecasts, 2018 to 2030, (USD Million
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Target disease prevalence
7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Target disease prevalence
7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Target disease prevalence
7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Target disease prevalence
7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Target disease prevalence
7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Target disease prevalence
7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Target disease prevalence
7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Target disease prevalence
7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Target disease prevalence
7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Target disease prevalence
7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. Target disease prevalence
7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Target disease prevalence
7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. Target disease prevalence
7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Target disease prevalence
7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Target disease prevalence
7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.2. Argentina
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Target disease prevalence
7.8.2.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. Target disease prevalence
7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Target disease prevalence
7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. Target disease prevalence
7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Target disease prevalence
7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company market share analysis, 2024
8.3.2. Thermo Fisher Scientific Inc.
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Invitae Corporation
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Qiagen N.V.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Illumina, Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Laboratory Corporation of America Holding
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Exact Sciences Corporation
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Rain Oncology Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Strata Oncology Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Xilis, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Variantyx, Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Bioserve
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Relay Therapeutics
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. Acrivon Therapeutics
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives

List of Tables
Table. 1 List of Abbreviation
Table. 2 North America precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 3 North America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 4 North America precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 5 U.S. precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 6 U.S. precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 7 U.S. precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 8 Canada precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 9 Canada precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 10 Canada precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 11 Mexico precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 12 Mexico precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 13 Mexico precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 14 Europe precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 15 Europe precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 16 Europe precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 17 UK precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 18 UK precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 19 UK precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 20 Germany precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 21 Germany precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 22 Germany precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 23 France precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 24 France precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 25 France precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 26 Italy precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 27 Italy precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 28 Italy precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 29 Spain precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 30 Spain precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 31 Spain precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 32 Denmark precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 33 Denmark precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 34 Denmark precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 35 Sweden precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 36 Sweden precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 37 Sweden precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 38 Norway precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 39 Norway precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 40 Norway precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 41 Asia Pacific precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 42 Asia Pacific precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 43 Asia Pacific precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 44 Japan precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 45 Japan precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 46 Japan precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 47 China precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 48 China precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 49 China precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 50 India precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 51 India precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 52 India precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 53 Australia precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 54 Australia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 55 Australia precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 56 Thailand precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 57 Thailand precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 58 Thailand precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 59 South Korea precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 60 South Korea precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 61 South Korea precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 62 Latin America precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 63 Latin America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 64 Latin America precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 65 Brazil precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 66 Brazil precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 67 Brazil precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 68 Argentina precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 69 Argentina precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 70 Argentina precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 71 Middle East & Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 72 Middle East & Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 73 Middle East & Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 74 South Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 75 South Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 76 South Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 77 Saudi Arabia precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 78 Saudi Arabia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 79 Saudi Arabia precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 80 UAE precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 81 UAE precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 82 UAE precision oncology market, by end use, 2018 - 2030 (USD Million)
Table. 83 Kuwait precision oncology market, by product type, 2018 - 2030 (USD Million)
Table. 84 Kuwait precision oncology market, by cancer type, 2018 - 2030 (USD Million)
Table. 85 Kuwait precision oncology market, by end use, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Precision Oncology: Market outlook
Fig. 9 Precision Oncology: Competitive Insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Precision Oncology Market driver impact
Fig. 15 Precision Oncology Market Restraint Impact
Fig. 16 Precision Oncology Market Strategic Initiatives Analysis
Fig. 17 Precision Oncology market: Product type movement analysis
Fig. 18 Precision Oncology market: Product type outlook and key takeaways
Fig. 19 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Precision Oncology market: Cancer type movement analysis
Fig. 22 Precision Oncology market: Cancer type outlook and key takeaways
Fig. 23 Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Cervical Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Precision Oncology market: End Use movement analysis
Fig. 30 Precision Oncology market: End Use outlook and key takeaways
Fig. 31 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Pharmaceutical & Biotechnology Companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Healthcare Data Companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 North America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 U.S. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Canada precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Mexico precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Europe precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 U.K. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Germany precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 France precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Italy precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Spain precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Sweden precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Norway precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Denmark precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Asia Pacific precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Japan precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 China precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 India precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Australia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Thailand precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 South Korea precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Latin America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Brazil precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Argentina precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Middle East and Africa. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Saudi Arabia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 South Africa precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 UAE precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Kuwait precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)